SOMAí Pharmaceuticals June 2023 Newsletter
Newsletter - June 2023
SOMAí had a highly active month in June as we started our product launch. Our?APIs have successfully completed six months of accelerated stability testing. We are offering a diverse range of APIs in numerous markets. Single-strain cultivars indicate our API product line and include the following:?
We are thrilled to announce the launch of our first line of oral solutions. The first product is?Sativa Dominant Oral Solutions with MCT Oil Base. Stay tuned as we launch the?Indica Dominant Oral Solutions with MCT Oil Base, SOMAí Fast Acting Oral Solutions, and?SOMAí Nano Emulsion Oral Solutions with Mint Flavonoids?later this year.?
Additionally, our?Vape Oils?have?entered stability. Moving up our initial scheduled launch to the end of 2023, we anticipate the opportunity to introduce this new offering to the patients. Our Vape Oils will include the following:
Learn more about our products in the catalogue .
During June, SOMAí underwent an?assessment conducted by?the?PSP inspection, which concluded that no significant concerns were identified. Now is just a short wait for the official GMP certificate, which we all anxiously anticipate, hopefully before the summer holiday. This achievement represents a noteworthy milestone in our journey, and until then, we keep validating more and more products.?
SOMAí?was thrilled to?partner with Cosma Cannabis, a Polish distributor of medical-grade cannabis products in Poland. The contract represents 1,000,000 euros in sales for SOMAí's 2024 goals to develop the fast-emerging medical cannabis markets of Poland.
SOMAí recently achieved a significant milestone with?the first Scientific Advisory Board meeting. Please welcome to the SOMAí team well-respected scientists and researchers specializing in medicinal cannabis, including Dr. David Meiri, Dr. Anne Katrin Schlag, Dr. Mauro Maccarrone, Dr. Arno Hazekamp, Dr. Hunter Land, Alexander Daske, Dr. Maria do Céu Costa, and Dr. Patricia Rijo who will be guiding our current absorption trials both in-vivo and in-vitro as well as the Sativex generic, but also creating other observational trials and clinical trials throughout the SOMAí development.
We are almost finished with the second phase of our?facility expansion, with room certification slated for August, designed to elevate our capabilities, broaden our product range, and create additional clean room production space. This expansion encompasses several key elements, including the establishment of a dedicated area for soft gel capsule production, the introduction of sublingual and transdermal tab production, the creation of a specialized room for vape cartridge and syringe filling, with the integration of two new primary and secondary packaging lines. Furthermore, we are incorporating high-speed bottling capabilities to optimize production efficiency and cater to the increasing market demands.?
SOMAí?Pharmaceuticals hosted?Open Doors Day?for industry professionals on July 2. The event provided insights into SOMAí's cutting-edge operations, showcasing the company's commitment to excellence in pharmaceutical production. We plan to make more Open Doors Days in the future, so stay tuned.
In June, we actively engaged in both offline and online activities. SOMAí Pharmaceuticals recently concluded a series of exciting events and opportunities that showcased our commitment to excellence and innovation in the pharmaceutical industry. Firstly, our CEO and Founder attended the?Global Investment Forum?in Berlin on June 27, 2023. Following the GIF, Michael captivated audiences at the?CB Club Berlin?on June 28 with an inspiring panel about how to successfully scale a cannabis business.
领英推荐
Continuing the momentum, our sales team participated in the?ICBC Berlin?on June 29, where we met industry professionals at our stand. And once again, Michael was speaking to a crowd for the biotech panel at ICBC. This event provided an exceptional opportunity to connect with our team and explore our launch of products.
Additionally, SOMAí has?sponsored a Cannabiscientia seminar?about Endocannabinoid System. Also, SOMAí Pharmaceuticals proudly participated in the exclusive live seminar "From Formulation Strategies to Regulatory Compliance and Beyond," featuring Anthony DeMeo, Director of Research and Development at SOMAí, in collaboration with Cannabiscientia SA. The seminar provided insights into cutting-edge formulation strategies for medical cannabis products, the importance of regulatory compliance in the industry, and navigating the evolving regulatory landscape. The event showcased SOMAí's commitment to scientific excellence, innovation, and compliance in delivering high-quality medical cannabis products. Overall, we had a great June and are excited for July.
SOMAí?- July highlights:?
We are thrilled to announce the opening of the?SOMAí Pharmaceuticals Office in Australia. As part of this endeavor, Michael Sassano is embarking on a business tour across various cities. From July, he will visit Perth, Brisbane, Sydney, and Melbourne. If you are interested in scheduling a meeting to explore potential collaborations with SOMAí Pharmaceuticals, please feel free to reach out to [email protected].
Furthermore, we would like to inform you that SOMAí Co-Founder and Chief Operating Officer, George Bellow , will be undertaking a business trip to France in July. If you would like to arrange a meeting during this time, kindly contact [email protected].
Check our latest useful links:
You can get information about SOMAí products and services in the?Product Catalogue
We are also thrilled to announce that we have done?extensive research on SOMAí Pharmaceuticals. You can read the complete research here:?SOMAí Equity Research
Latest articles from our CEO, Michael Sassano
Area sales manager
1 年Sound great